Sacituzumab Govitecan In TNBC

This study is testing sacituzumab govitecan, an antibody-drug combination treatment, in patients with triple-negative breast cancer (TNBC) — a type of breast cancer that does not respond to hormone or HER2-targeted therapies — who have not yet received any treatment for their cancer. **You may be eligible if...** - You are 18 or older - You have been newly diagnosed with invasive breast cancer that tests negative for estrogen receptors, progesterone receptors, and HER2 (triple-negative breast cancer) - You have not yet received any treatment for your breast cancer - Your cancer has been confirmed by biopsy **You may NOT be eligible if...** - Your breast cancer tests positive for estrogen receptors, progesterone receptors, or HER2 - You have already received treatment for this breast cancer - You are pregnant - You have serious organ problems (heart, liver, kidneys) - You have another active cancer Talk to your doctor to see if this trial is right for you.